Another promising approach for hard-to-treat blood cancers

Pinterest LinkedIn Tumblr +

For patients with some hard-to-treat blood cancers, a new “off-the-shelf” immunotherapy is achieving promising results.

A clinical trial of the developmental drug Glofitamab has shown it can produce a durable “complete response” – meaning the cancer became undetectable – in patients with relapsed or treatment resistant B-cell lymphomas.

One option for these patients is CAR T-cell therapy – also an immunotherapy but one which involves collecting the patient’s T-cells and reprogramming these cells in a laboratory to form a cancer-fighting infusion.

Peter Mac’s Group Leader for Aggressive Lymphoma, Dr Michael Dickinson, said Glofitamab had shown early impressive results in a similar group of patients.

“CAR T-cell therapy is a game-changer for how we treat blood cancer patients who have exhausted conventional treatment options,” said Dr Dickinson.

“However the complexity of CAR T-cell therapy has highlighted the need for more off-the-shelf options and, with Glofitamab, we are now starting to see these emerge.

“These trial results are impressive and support ongoing assessment of Glofitamab in larger scale trials, both as a single agent and in combination with other drugs.”

The 171 participants in the Phase I (dose finding) clinical trial had B-cell non-Hodgkin lymphoma which had relapsed or stopped responding to conventional treatments.

More than half (53.8%) showed an anti-cancer response to the drug, and more than a third (36.8%) had a complete response – meaning their cancer became undetectable.

The response rate, and complete response rate, increased to 65.7% and 57.1% respectively in a group who received the dose to be tested in a future Phase II trial.

Among patients with a complete response, for most (84.1%) this was enduring and the longest tracked patient was cancer free for more than two years.

The drug’s most common adverse event was cytokine release syndrome – which is also a potential side-effect of CAR T-cell therapy requiring close management.

A paper describing these trial results in full is published in the Journal of Clinical Oncology.


Source: Peter Mac

Share.

About Author

ONA Editor

The ONA Editor curates oncology news, views and reviews from Australia and around the world for our readers. In aggregated content, original sources will be acknowledged in the article footer.

Leave A Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.